Immix Biopharma Management
Management criteria checks 3/4
Immix Biopharma's CEO is Ilya Rachman, appointed in Jan 2012, has a tenure of 12.33 years. total yearly compensation is $1.13M, comprised of 39.5% salary and 60.5% bonuses, including company stock and options. directly owns 4.28% of the company’s shares, worth $2.43M. The average tenure of the management team and the board of directors is 3.2 years and 3 years respectively.
Key information
Ilya Rachman
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 39.5% |
| CEO tenure | 12.3yrs |
| CEO ownership | 4.3% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$1m | US$446k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$9m |
| Dec 31 2022 | US$2m | US$425k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$397k | US$193k | -US$24m |
Compensation vs Market: Ilya's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD661.15K).
Compensation vs Earnings: Ilya's compensation has been consistent with company performance over the past year.
CEO
Ilya Rachman (50 yo)
12.3yrs
Tenure
US$1,129,881
Compensation
Dr. Ilya Rachman, MD, PhD, MBA, Co-Founder, Chairman and Chief Executive Officer at Immix Biopharma, Inc since 2012. Dr. Rachman is a pioneering physician/scientist, cell biologist and among the first to f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$1.13m | 4.28% $ 2.4m | |
| CFO & Director | 3.2yrs | US$1.13m | 1.06% $ 602.1k | |
| Chief Medical Officer & Head of Clinical Development | 2.9yrs | US$104.42k | 0% $ 0 | |
| Co-Founder | no data | no data | 3.41% $ 1.9m | |
| Scientific Co-Founder | 12.3yrs | no data | 3.43% $ 1.9m | |
| Head of Chemistry | 7yrs | no data | no data | |
| Chief Medical Officer of Cell Therapy | 1.3yrs | no data | no data | |
| Head of Cell Thearpy Manufacturing | 1.3yrs | no data | no data |
3.2yrs
Average Tenure
61yo
Average Age
Experienced Management: IMMX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$1.13m | 4.28% $ 2.4m | |
| CFO & Director | 3.2yrs | US$1.13m | 1.06% $ 602.1k | |
| Independent Director | 2.9yrs | US$173.63k | 0.085% $ 48.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11.3yrs | US$156.38k | 3.27% $ 1.9m | |
| Independent Director | 2.9yrs | US$180.64k | 0.25% $ 142.1k | |
| Lead Independent Director | 2.9yrs | US$429.37k | 0.66% $ 375.7k | |
| Independent Director | 4.5yrs | US$159.88k | 0.038% $ 21.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Board: IMMX's board of directors are considered experienced (3 years average tenure).